Member Info for draft

if you look in the website, it is on the LCG website no ramping at all, I just copied from their website

LCG launches powerful new platform We're proud to announce that London Capital Group has successfully undertaken a major restructuring of all parts of its business including the introduction of a new senior management team, a clearer strategic focus and the addition of cutting-edge trading technology. The company has consolidated its Capital Spreads and London Capital Group brands under one global brand identity and will now operate as LCG. For more information on these exciting developments, visit LCG.com or watch the LCG Trader platform video. With competitive spreads on a wide range of global markets and a powerful new platform available across all devices, LCG is well positioned to move from strength to strength in 2016.

Mr. Lobo steps into his new role as the Head of Business Development with immediate effect – he will be based out of London. He comes over to London Capital Group from IronFX, having worked previously in its Spain Representative Office for nearly three years, dating back to 2013. plenty of new staff! business must be good

Finance Magnates has learned that the UK-based FX, spread betting and CFDs provider London Capital Group has secured the services of Alex de Lusignan as its newest Senior Business Development Manager. Based in the City, Alex brings a long experience to LCG, having worked in several roles across the UK, Switzerland and South Africa, for a variety of companies including Swissquote, Julius Baer and UniCredit. Alex will focus on growth opportunities in several locations and will work closely with Emilio Lobo who joined LCG back in April to take on the position of its Head of Business Development. Mr. Lusignan joins London Capital Group from FCA-regulated

lol - get TD direct

thats a buy just in the wrong colour

I expect a surge this afternoon - lets see

Boooooommmm times

No problem buying

StonePrevent The second product being developed by the Target, StonePrevent, which is at an earlier stage of development than StoneChecker, uses the same patented TexRAD algorithm to provide information on the patient’s stone which, combined with blood test results, 24 hour metabolic urine test results and an online dietary and lifestyle assessment, provides patients and their clinicians with evidence based advice to assist them with educing the risk of recurrent kidney stones. This is in line with the recent recommendations from the merican Urology Association that patients with first time kidney stones should undergo metabolic screening. espite this guidance, full metabolic screening is not always offered to patients and those that do undergo blood nd urine testing may not receive complementary dietary and lifestyle testing, which has an important role in providing personalised on-going advice. StonePrevent is a consumer facing product accessed via a website and a mobile platform that will be marketed to urologists and renal physicians as well as directly to patients.

StoneChecker uses an innovative, patented software plug-in (which is licenced from TexRAD for use in the field of urolithiasis) based on an algorithm comprising of TexRAD texture analysis, in addition to other important clinical markers such as stone volume and distance from skin surface, to automatically interrogate a patient’s CT scan, providing important new diagnostic information for patients and their clinicians, allowing better decision-making regarding the optimal use of lithotripsy. This software has been developed further during the course of 2016 with the creation of a multi slice analysis tool. This has increased the speed of analysis of a patient’s CT scan so that the edges of the stones are automatically recognised by the StoneChecker software

platforms, you got to call your broker, dont miss out

Accordingly, there is a strong opportunity for a kidney stone focused businesses to provide solutions to the healthcare needs that patients and clinicians are demanding. The Target is developing two complementary products, StoneChecker and StonePrevent, which the Target hopes will enhance current clinical practice and help doctors to better manage and prevent this painful condition.

got an APP as well - read the prospectus!

The StoneChecker plug-in will be ava ilable either for purchase on a serv er with local unlimited access or on a server or cloud based system where access is on a charge per-use basis. The upfront cost of purchasing the StoneChecker so ftware so that it can accessed locally an unlimited number of times is expected to be £15,000 with annual recurring revenues based on software maintenance and upgrades, which may include impr ovements to the TexRAD algorithm based on additional patient data. The intention is to char ge a maintenance fee of between £1,500 and £2,000 per year depending on the updates offered. If no additional updates are offered then the maintenance fee may be lowered. Discussions have taken place at length, both inter nally between the Director s, some of whom are already actively involved with other TexRAD softwar e and as such are aware of the key pricing issues, and externally with advisors such as the Oxford Stone Group, as to what is a feasible price for a one- off purchase of the plug-in. Following these discus sions, the Directors believe that £15,000 is an appropriate price, taking into account the potential cost saving that healthcare clinics may receive following installation of the plug-in as well as a reduction in clinician time. The expected cost of accessing the StoneChecker software on a charge per-use basis is approximately £30 per use, with price levels based on volume bands. Fees will then be invoiced to those customers who have a pay per-use package on a quarterly basis. If the pay-per-click software is accessing using a locally installed server version, a nominal amount will be paid upfront to install the software. If the pay -per-click software is accessed on the cloud based system, it is expected that upfront fees of £1,000 will be charged to include access to the web-based version and servicing of the software.

One market leader in the manufacture and sale of lithotripsy solutions has expressed a high level of interest in the StoneChecker product subject to due diligence when the commercial product is available following completion of the patient studies. In the US, there are multiple opportunities to partner with niche companies in the radiology market, such as PCAs (personal care agency) providers, x-ray scanner companies and contract media pharmaceutical companies

in my opinion

Trevor runs a tight ship - we are cashed up and ready for take off

just the start here and new director has contacts in the kidney software sphere

last year!